Lenalidomide Demonstrates Promising Activity in Pediatric Gliomas/Astrocytomas

The immunomodulatory agent lenalidomide (Revlimid) appeared clinically active and tolerable in pilocytic astrocytomas and optic pathway gliomas in a cohort of pediatric patients who progressed following initial therapy, according to findings from a phase 2 trial (NCT01553149) published in the Journal of Clinical Oncology.

Read more: https://www.cancernetwork.com/view/lenalidomide-demonstrates-promising-activity-in-pediatric-gliomas-astrocytomas